Myeloid-conditioning using Toll-like receptor agonists to restore immune potency against melanoma.

被引：0
|
作者：
Foureau, David [1 ,2 ]
Carpenter, Kendall [1 ]
Amin, Asim [3 ]
Guo, Fei [2 ]
White, Richard [4 ]
Salo, Jonathan [4 ]
机构：
[1] Carolinas Healthcare Syst, Gen Surg Res, Charlotte, NC USA
[2] Carolinas Healthcare Syst, Immune Monitoring Core Lab, Charlotte, NC USA
[3] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA
[4] Carolinas Healthcare Syst, Surg Oncol, Charlotte, NC USA
来源：
JOURNAL OF IMMUNOLOGY | 2014年 / 192卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
TUM4P.926
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation
    Gu, Liuwei
    Kong, Xiaojie
    Li, Mengyan
    Chen, Rui
    Xu, Ke
    Li, Guo
    Qin, Yulin
    Wu, Li
    CHEMICAL COMMUNICATIONS, 2024, 60 (42) : 5474 - 5485
  • [32] MEDI 106-Impact of secondary structure of agonists of Toll-like receptor 9 on immune stimulatory activity
    Yu, Dong
    Putta, Mallikarjuna R.
    Bhagat, Lakshmi
    Wang, Daqing
    Dai, Meiru
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [33] Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.
    Patel, Sapna Pradyuman
    Petroni, Gina R.
    Gaughan, Elizabeth Mary
    Grosh, William W.
    Gnjatic, Sacha
    Hwu, Patrick
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists
    Zhong, RuiKun
    Li, Hongying
    Messer, Karen
    Lane, Thomas A.
    Zhou, Jiehua
    Ball, Edward D.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 737 - 744
  • [35] Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists
    RuiKun Zhong
    Hongying Li
    Karen Messer
    Thomas A. Lane
    Jiehua Zhou
    Edward D. Ball
    Cancer Immunology, Immunotherapy, 2015, 64 : 737 - 744
  • [36] Role of toll-like receptor 2 in immune response against Pseudomonas aeruginosa and its pathological characteristics
    Ahmadishoar, Shiva
    Kariminik, Ashraf
    INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 2024, 62 (09) : 705 - 712
  • [37] Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo
    Lan, Tao
    Wang, Daqing
    Bhagat, Lakshmi
    Philbin, Victoria J.
    Yu, Dong
    Tang, Jimmy X.
    Putta, Mallikarjuna R.
    Sullivan, Tim
    La Monica, Nicola
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11 (06) : 1049 - 1058
  • [38] Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses
    Ou, Ben S.
    Baillet, Julie
    Interrante, Maria V. Filsinger
    Adamska, Julia Z.
    Zhou, Xueting
    Saouaf, Olivia M.
    Yan, Jerry
    Klich, John H.
    Jons, Carolyn K.
    Meany, Emily L.
    Valdez, Adian S.
    Carter, Lauren
    Pulendran, Bali
    King, Neil P.
    Appel, Eric A.
    SCIENCE ADVANCES, 2024, 10 (32):
  • [39] Variability among Macaca fascicularis in the innate immune response to Toll-like receptor 4 (TLR4) agonists
    Frevert, Charles Wayne
    Hukkanen, Renee
    Mongovin, Steve
    Larsen, Kay
    Agy, Mike
    Martin, Thomas
    Wurfel, Mark
    FASEB JOURNAL, 2008, 22
  • [40] A multipeptide vaccine plus toll-like receptor agonists LPS or polylCLC in combination with incomplete Freund's adjuvant in melanoma patients
    Melssen, Marit M.
    Petroni, Gina R.
    Chianese-Bullock, Kimberly A.
    Wages, Nolan A.
    Grosh, William W.
    Varhegyi, Nikole
    Smolkin, Mark E.
    Smith, Kelly T.
    Galeassi, Nadejda, V
    Deacon, Donna H.
    Gaughan, Elizabeth M.
    Slingluff, Craig L., Jr.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345